Back to top
more

Radius Recycling, Inc. (RDUS)

(Delayed Data from NSDQ)

$16.40 USD

16.40
162,707

+0.21 (1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $16.39 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (184 out of 250)

Industry: Waste Removal Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS

by Zacks Equity Research

Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.

Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines

by Zacks Equity Research

Radius (RDUS) reports a year-over-year wider Q3 loss and misses on sales. The company also lowers guidance for lead drug Tymlos.

Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of -74.07% and -7.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Biotech Stocks' Q3 Earnings on Nov 8: VTRS, EDIT & More

by Kinjel Shah

Let us look at four drug/biotech companies, VTRS, RDUS, AXSM and EDIT, which are gearing up for their earnings release.

Earnings Preview: Radius Health (RDUS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Radius (RDUS) Up On Positive Data From Breast Cancer Study

by Zacks Equity Research

Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.

Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal

by Zacks Equity Research

Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

Radius Health (RDUS) Stock Jumps 7.1%: Will It Continue to Soar?

by Zacks Equity Research

Radius Health (RDUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

Radius (RDUS) reports a narrower loss but misses on sales in the second quarter. The company also lowers guidance for lead drug Tymlos.

Radius Health (RDUS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of 10.26% and -12.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Radius Health (RDUS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag

by Zacks Equity Research

Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.

Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Radius Health (RDUS) delivered earnings and revenue surprises of 19.05% and -5.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Radius Health (RDUS) Up 14.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radius Health (RDUS) Soars 14.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Radius Health (RDUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

KemPharm (KMPH) Soars on FDA Nod for ADHD Treatment, Azstarys

by Zacks Equity Research

The FDA approves KemPharm's (KMPH) NDA for Azstarys for the treatment of attention deficit hyperactivity disorder in patients aged six years and older. Shares rise.

ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss

by Zacks Equity Research

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.

Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

Pacira's (PCRX) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Exparel sales rise year over year.

Will Radius Health (RDUS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics

by Zacks Equity Research

Zacks Industry Outlook Highlights: Radius Health, USANA Health Sciences, Organogenesis Holdings, Turning Point Therapeutics and Oncternal Therapeutics

Kinjel Shah headshot

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

by Kinjel Shah

Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry in 2021. However, with demand trends expected to improve, USNA, RDUS, ONCT, ORGO and TPTX may prove to be good additions to one's portfolio.

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

by Zacks Equity Research

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.